Drugs / Onfasprodil
Onfasprodil
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05666687 | Jan → Nov 2023 | major depressive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05454410 | Mar → Nov 2023 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04722666 | Jul 2021 → Sep 2023 | major depressive disorder | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT03756129 | Feb 2019 → Mar 2020 | major depressive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Onfasprodil | “Onfasprodil (MIJ821) is a highly potent and novel selective NR2B subunit negative allosteric modulator.” PMID 40767837 ↗ Aug 2025 |
| Known as | CAD-9271 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095074 ↗ |
| Known as | MIJ821 | “Onfasprodil (MIJ821) is a highly potent and novel selective NR2B subunit negative allosteric modulator.” PMID 40767837 ↗ Aug 2025 |
| Known as | MIJ821-NX | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095074 ↗ |
| Known as | NVP-MIJ821-NX | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095074 ↗ |
| Action | Inhibit | “Onfasprodil (MIJ821) is a highly potent and novel selective NR2B subunit negative allosteric modulator.” PMID 40767837 ↗ Aug 2025 |
| Modality | Small molecule | — CHEMBL5095074 ↗ |
| Route | Intravenous | “Adults with TRD who did not respond to ≥2 antidepressants were randomized (3:3:3:3:6:4) to receive a 40-minute intravenous infusion of onfasprodil 0.16 mg/kg weekly (n = 11),...” PMID 40767837 ↗ Aug 2025 |